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Disturbances of gastric and intestinal motor functions 
such as gastroparesis, functional dyspepsia, enteric dys-
motility, IBS and constipation affect a large proportion 
of the population worldwide, impair quality of life and 
cause considerable health-care costs1,2. Assessment of 
gastrointestinal motility in these patients can serve to 
establish diagnosis and to guide therapy. Comprehensive 
consensus papers published in 2008 (REF. 3) and 2011 
(REF. 4) detailed how to evaluate and interpret gastric, 
small intestinal and colonic motility by intraluminal 
measurements and transit tests in clinical practice.
Advances in diagnostic techniques for the evaluation 
of gastrointestinal motor function necessitate an update 
about indications for and selection and performance 
of currently available tests, how motility disorders can 
be differentiated and classified based on these tests and 
how the results guide treatment decisions, as noted in this 
Consensus Statement. A panel of international motility 
experts has re-examined these issues and provides con-
cise information on test principles, practical performance 
and interpretation of individual tests (BOX 1). Further 
details on these topics will be provided in  technical 
 position statements that will be published separately.
Methods
This Consensus Statement is part of a series of papers 
on gastrointestinal motility initiated by the International 
Working Group for Disorders of Gastrointestinal Motility 
and Function. Authors were invited based on their experi-
ence and reputation in the field and chosen to cover the 
intended scope of the manuscript; they represent experts 
from many European countries, North America, Australia 
and China. Experts on gastric, small bowel and colonic 
motility disorders first developed statements regarding 
evaluation of transit and contractility of the respective 
segments of the gastro intestinal tract, which were based 
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Advances in the diagnosis and 
classification of gastric and intestinal 
motility disorders
Jutta Keller1*, Gabrio Bassotti2, John Clarke3, Phil Dinning4, Mark Fox5, 
Madhusudan Grover6, Per M. Hellström7, Meiyun Ke8, Peter Layer1, 
Carolina Malagelada9, Henry P. Parkman10, S. Mark Scott11, Jan Tack12, 
Magnus Simren13, Hans Törnblom13 and Michael Camilleri6; on behalf of the 
International Working Group for Disorders of Gastrointestinal Motility and Function
Abstract | Disturbances of gastric, intestinal and colonic motor and sensory functions affect 
a large proportion of the population worldwide, impair quality of life and cause considerable 
health-care costs. Assessment of gastrointestinal motility in these patients can serve to establish 
diagnosis and to guide therapy. Major advances in diagnostic techniques during the past 
5–10 years have led to this update about indications for and selection and performance of 
currently available tests. As symptoms have poor concordance with gastrointestinal motor 
dysfunction, clinical motility testing is indicated in patients in whom there is no evidence of 
causative mucosal or structural diseases such as inflammatory or malignant disease. Transit tests 
using radiopaque markers, scintigraphy, breath tests and wireless motility capsules are 
noninvasive. Other tests of gastrointestinal contractility or sensation usually require intubation, 
typically represent second-line investigations limited to patients with severe symptoms and are 
performed at only specialized centres. This Consensus Statement details recommended tests as 
well as useful clinical alternatives for investigation of gastric, small bowel and colonic motility. 
The article provides recommendations on how to classify gastrointestinal motor disorders on 
the basis of test results and describes how test results guide treatment decisions.
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on already available consensus statements3,4. Consensus 
statements from other gastrointestinal societies or expert 
groups were searched for and included when appropriate, 
for example, if they were published more recently or if they 
covered relevant areas not specifically addressed in the 
previous documents3,4. Moreover, an updated literature 
search using PubMed and Medline was performed cen-
trally by the corresponding author (J.K.) with additions 
from the co-authors. The literature search started on the 
date specified as the end date of the lite ature searches per-
formed for two previously published consensus papers3,4 
(that is, 1 Jan 2008 for intraluminal measure ments of 
gastrointestinal motility and 1 Jan 2010 for transit tests); 
the search covered the period until 14 Apr 2016 and was 
generally limited to human studies. The literature search 
revealed 1,111 publications, of which 202 were selected 
on the basis of study quality (which did not include a for-
mal evaluation, but the level of evidence was assessed in 
line with the Oxford Centre for Evidence-based Medicine 
(https://www.cebm.net/2009/06/oxford-centre- evidence-
based-medicine-levels-evidence-march-2009/) and were 
made available to all authors. Low-quality studies were 
also considered if the topic was deemed rele vant and 
not covered otherwise. The literature search on gastric 
emptying included the following terms, revealing 624 
papers: “gastric emptying”, “gastro paresis”, “dumping”, 
“measurement”, “test”, “evalu ation” and “diagnosis”. The 
literature search on intra luminal tests of gastric motility 
included the following terms, revealing 67 papers: “gas-
tric”, “antral”, “antro duo denal”, “antro duodenojejunal”, 
“motility”, “contraction”, “intraluminal” and “mano metry”. 
The literature search on small bowel transit included the 
following terms, revealing 130 papers: “orocaecal transit”, 
“OCCT”, “small bowel transit”, “intestinal transit”, “meas-
urement”, “test”, “evaluation”, “diagnosis”, “sensitivity” and 
“specificity”. The literature search on intraluminal tests of 
small bowel motility included the following terms, reveal-
ing 13 papers: “small bowel”, “antroduodenal”, “antro-
duodenojejunal”, “ intestinal”, “intraluminal”, “motility” 
and “manometry”.
The literature search on colonic transit included the 
following terms, revealing 222 papers: “colonic transit”, 
“Hinton”, “measurement”, “test”, “evaluation”, “diagno-
sis”, “sensitivity” and specificity. The literature search 
on intraluminal tests of colonic motility included the 
follow ing terms, revealing 55 papers: “colonic”, “ motility”, 
“contraction”, “intraluminal” and “manometry”.
Statements were distributed via e-mail, and each 
author had to confirm full agreement, minor concerns 
or disagreement in writing. Concerns or disagreement 
had to be explained. All statements with at least one 
author in disagreement or more than three authors 
with minor concerns were modified after discussion in 
conference calls and in a face-to-face meeting at United 
European Gastroenterology Week in Vienna, Austria, 
in October 2016. It was required that no more than one 
author disagree with the final Consensus Statement for 
it to be included in the final version of the manuscript. 
Statements contain crucial information on the respective 
topic and/or give recommendations on when or how to 
perform and interpret motility tests. They are marked 
as bold bulleted points throughout the manuscript. All 
authors consented to the final version of the manuscript, 
including comments.
Clinical application of motility testing
• Before investigation of gastrointestinal motor 
function, mucosal or structural diseases such as 
inflammatory or malignant disease should be 
excluded.
Symptoms of gastrointestinal motor disorders are 
nonspecific: dysmotility cannot be differentiated from 
inflammatory or malignant disease on the basis of 
patient history alone. For example, epigastric pain, early 
satiety and abdominal fullness are typical symptoms 
of gastro paresis but can also be due to gastroduodenal 
ulcers or gastric cancer. Moreover, inflammatory dis-
eases of the small and large bowel are associated with 
delayed gastric emptying, which can be reversible after 
treatment of inflammation5,6. Thus, it is important to 
first exclude other aetiologies, in particular, mucosal and 
obstructive lesions, by appropriate investigations such 
as upper and lower gastrointestinal endoscopy, imaging 
techniques and laboratory investigation. Such tests are 
mandatory in patients with ‘red flags’ (that is, weight 
loss, low haemoglobin levels and substantial episodes of 
vomiting) but should also be performed if the motility 
tests are invasive or symptoms are severe. In patients 
with moderate complaints and no alarm symptoms, 
noninvasive motility testing might be considered. The 
selection of tests will also be influenced by availabil-
ity and the costs of  diagnostic procedures in different 
health-care systems.
In general, motility investigations are usually limited 
to patients with relevant complaints that can be related to 
dysmotility and that markedly affect quality of life, nutri-
tion, social function or work productivity and, rarely, to 
increased mortality7,8. As with any diagnostic procedure, 
they are justified only if the results can be expected to 
influence clinical management.
Author addresses
1Israelitic Hospital, Academic Hospital University of Hamburg, Orchideenstieg 14, 
22297 Hamburg, Germany. 
2University of Perugia, Piazza dell’Università, 1, 06121 Perugia, Italy. 
3Stanford University, 900 Blake Wilbur Dr, Palo Alto, CA 94304, USA. 
4Flinders Medical Centre, GPO Box 2100, Adelaide 5001, Australia. 
5University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland, and St. Claraspital, 
Kleinriehenstrasse 30, 4058 Basel, Switzerland. 
6Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA. 
7Uppsala University Hospital, Building 40, SE‑75185, Uppsala, Sweden. 
8Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng 
District, Beijing, 100730, China. 
9University of Barcelona, Passeig de la Vall d’Hebron, 119–129, 08035 Barcelona, Spain. 
10Temple University Hospital, 3401 N Broad St, Philadelphia, PA 19140, USA. 
11Queen Mary University of London, The Wingate Institute, 26 Ashfield Street, 
Whitechapel, London E1 2AJ, UK. 
12University Hospital Gasthuisberg, University of Leuven, Herestraat 49, 3000 Leuven, 
Belgium. 
13Sahlgrenska Academy, University of Gothenburg, Blå stråket 5, 41345 Gothenburg, 
Sweden.
C O N S E N S U S  S TAT E M E N T
292 | MAY 2018 | VOLUME 15 www.nature.com/nrgastro
©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
Investigation of gastric motor function
Indications and clinical importance
Tests of gastric motor function comprise gastric  emptying 
tests and intraluminal measurements of contractility.
• Clinical investigation of gastric motor function is 
indicated in patients in whom upper gastrointestinal 
endoscopy is normal or does not provide a definitive 
diagnosis and in patients in whom there is suspicion 
of gastroparesis, unexplained nausea and vomiting 
or dumping syndrome.
• Abdominal symptoms of accelerated and delayed gas­
tric emptying are similar, such that gastric empty­
ing tests can be necessary for delineation of motor 
dysfunction.
Symptoms suggestive of delayed gastric emptying 
include early satiety, nausea, vomiting, regurgitation, 
bloating, postprandial fullness, visible upper abdom-
inal distention, abdominal pain and weight loss1,9. 
Most patients with rapid gastric emptying present with 
abdominal symptoms that mimic those of gastro pare-
sis10,11. Suspicion of gastroparesis is further supported by 
identify ing risk factors, for example, long-standing diabe-
tes mellitus9. Conversely, suspicion of gastric dumping is 
supported by a history of upper gastrointestinal surgery12. 
However, in a large retrospective study in >600 patients 
with dyspepsia, the majority of patients with symptoms 
in association with rapid gastric emptying had no identi-
fiable cause11. Furthermore, upper gastrointestinal symp-
toms had a poor clinical specificity relative to the actual 
rate of gastric emptying on scintigraphy, underlining the 
need for function testing to guide treatment. In particu-
lar, the positive predictive value of clinical suspicion for 
delayed gastric emptying was only 29%11.
• The diagnosis of gastroparesis requires objective 
evidence of clearly delayed gastric emptying in 
symptomatic patients.
Because accelerated, normal and delayed gastric 
emptying cannot be differentiated reliably based on 
type or severity of gastrointestinal symptoms, objective 
measurement of clearly delayed gastric emptying (gas-
tric emptying time increased above the upper level of 
normal) using well-validated techniques such as gastric 
emptying scintigraphy (FIG. 1) is required for diagnosis 
of gastroparesis. To obtain a more specific symptom 
pattern and a better separation from functional dys-
pepsia with delayed emptying, gastroparesis has been 
proposed to require a stricter definition (for exam-
ple, >3 standard deviations above the mean value in 
healthy volunteers)13.
The merit of gastric emptying studies for clinical 
management has been questioned because of variations 
in the reports of association between gastric emptying 
rates and symptoms. Several studies published dur-
ing the past 7 years have shown a positive association 
between symptoms of gastroparesis and gastric emptying 
times14–19. Measurement of gastric emptying can also pre-
dict responsiveness to different therapeutic options20,21. 
For example, the presence of slow gastric emptying in 
patients with functional dyspepsia was associated with 
poor response to antidepressant medications that  target 
visceral hypersensitivity21. On the other hand, one sys-
tematic literature review that used multiple methods, 
various symptom instruments and diverse treatments 
showed that most drugs that improved idiopathic and 
diabetic gastroparesis failed to show a statistically 
significant relation ship with the degree of symptom 
improvement and acceleration of gastric emptying 
across studies22.
Some groups have observed that the association 
between clinical improvement and acceleration of gas-
tric emptying depends on the aetiology of gastropare-
sis20,23, which could partly explain inconsistent findings 
across studies22. Moreover, the modes of action of drugs 
used for acceleration of gastric emptying are extremely 
heterogeneous and potentially induce dysfunctions that 
cause symptoms. For example, motilin receptor agonists 
markedly accelerate gastric emptying but simultaneously 
impair gastric accommodation and can induce dyspep-
tic symptoms1. Several additional factors other than a 
global delay in gastric emptying — such as antral disten-
sion, antral hypomotility, gastric dysrhythmias, visceral 
hypersensitivity or psychological disturbances — could 
explain, in part, the symptoms experienced by patients 
with gastroparesis24.
• In patients with upper gastrointestinal surgery, 
diagnosis of dumping syndrome can be made on 
the basis of typical symptoms and findings such 
as post prandial hypoglycaemia or hypotension. 
In unclear cases, provo cation tests that prove dump­
ing syndrome are the basis of diagnosis, which is sup­
ported by evidence of accelerated gastric emptying, 
 preferably of liquids.
Dumping syndrome is a common complication of 
oesophageal, gastric or bariatric surgery and includes 
early and late dumping symptoms12. Early dumping 
occurs within 1 h after eating, when rapid emptying of 
food into the small intestine triggers rapid fluid shifts 
into the intestinal lumen and release of gastrointestinal 
Box 1 | Key advances in gastric and intestinal motility disorders
• Symptoms have poor concordance with gastrointestinal dysfunction on clinical 
investigations of gastrointestinal motility and function, underlining the need for 
testing to guide treatment
• Scintigraphy is the reference standard for measurement of gastric emptying; 
13C-gastric emptying breath tests can be used alternatively
• For all gastrointestinal function tests, adherence to adequately validated, 
standardized study protocols is crucial
• In patients with therapy-resistant constipation under consideration for colectomy, 
major disorders of upper gastrointestinal motility and evacuation disorders negatively 
influence therapeutic outcome and should, therefore, be excluded
• The presence of abnormal gastrointestinal function on clinical investigation can direct 
management and predict responsiveness to medical therapy in several conditions
• Valid reference values are available for many investigations of gastrointestinal 
motility (particularly, gastric, colonic and anorectal function) based on results from 
healthy individuals and patient data, thus defining definitively pathological results
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hormones, resulting in gastrointestinal and vasomotor 
symptoms. Late dumping occurs 1–3 h after carbo-
hydrate ingestion and is caused by an incretin- driven 
hyperinsulinaemia. According to clinical experi ence, 
in patients with typical symptoms after surgery, gastric 
emptying tests (FIGS 1,2) usually add little to the diagno-
sis. However, nearly 80% of patients with rapid gastric 
emptying according to scintigraphy had no identi fiable 
underlying cause for the accelerated empty ing even 
though one-quarter of these patients had associ ated 
hypoglycaemia11. Liquid test meals might better detect 
acceleration of early gastric emptying; studies using 
solid meals generally have low sensitivity and specificity 
for detecting accelerated gastric emptying12,25.
• Investigation of gastric emptying can be useful in 
the following situations: poorly controlled diabetes 
mellitus; severe GERD unresponsive to acid suppres­
sants (particularly before fundoplication); systemic 
sclerosis; after lung transplantation; Parkinson dis­
ease; general ized gastrointestinal motility disor­
ders; and patients under consideration for intestinal 
or colonic surgery or transplantation because of 
 motility disorders.
In these conditions, delayed gastric emptying can 
be clinically relevant even without typical symptoms of 
gastro paresis, as the test identifies gastric dysfunction 
that could have clinical or therapeutic implications. 
Thus, impaired coordination between nutrient delivery 
to the duodenum and onset of insulin effect can impair 
glycaemic control in patients with insulin-dependent 
diabetes and gastroparesis9. Delayed gastric emptying 
could cause gastro-oesophageal reflux and regurgita-
tion in a subset of patients with GERD26 and systemic 
sclerosis27. Lung transplant recipients can have mark-
edly impaired gastric emptying (secondary to vagal 
injury) with a risk of aspiration and post-transplant 
sequelae28. Delayed gastric emptying contributes sub-
stantially to fluctuations in symptom control in patients 
with Parkinsonism on long-term levodopa therapy29. 
In patients with generalized gastrointestinal motility 
disorders, particularly in those under consideration 
for abdominal surgery because of the motility dis order 
(for example, colonic inertia), knowledge of gastric 
 involvement is required to individualize therapy.
• Investigation of antral or antropyloroduodenal con­
traction patterns should be considered in patients 
with severely impaired function and marked symp­
toms in whom knowledge of the pathophysiology 
and/or severity of a gastric or gastrointestinal  motility 
 disorder is required for patient management.
Detailed investigation of gastric contractility generally 
requires invasive techniques such as intraluminal mano-
metry (including stomach and small bowel) and should, 
therefore, be limited to patients with severe symptoms. 
Clinically relevant information includes identification of 
gastric involvement in systemic sclerosis with reduced 
antral contraction amplitude (on average, <40 mmHg) and 
the selection of dietary recommendations and identifi-
cation of sites for enteral feeding3 (for example, in the 
jejunum in patients with severe antral hypomotility).
Recommended diagnostic approaches
• Scintigraphy is the reference standard for  measurement 
of gastric emptying.
A consensus report24 has recommended a standardized 
protocol for the performance of gastric emptying scinti-
graphy in the USA and has provided normal values. 
Accordingly, gastric emptying scintigraphy should be 
performed with a low-fat, egg white meal (~240 kcal, 2% 
fat) with imaging at 0 h, 1 h, 2 h and 4 h to assess empty-
ing of solids. The 1 h scan is used to detect rapid gastric 
emptying (percentage retention <30%) and the 2 h and 
4 h scans are used to detect delayed gastric emptying 
(retention >60% or >10%, respectively). A second well- 
validated protocol has been established by the Mayo 
Clinic, USA30, and uses a 320 kcal, 30% fat meal (FIG. 1). 
However, even in the USA, despite society guidelines, 
many centres continue to perform suboptimal studies 
(duration 1–2 h) that undermine the quality and utility of 
the test4. In most other countries, including the European 
ones, there are no widely accepted standard procedures. 
Nature Reviews | Gastroenterology & Hepatology
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Figure 1 | Representative examples of gastric emptying 
as assessed using scintigraphy. Standardized 
scintigraphic study of gastric emptying of solids with 
consumption of a 320 kcal radiolabelled meal (scrambled 
eggs labelled with 99mTc; Mayo Clinic protocol30) and 
imaging over 4 h. In the individual with normal gastric 
emptying (GE) (left panel), large amounts of the meal are 
emptied from the stomach at 2 h, and GE is completed at 
4 h. In the individual with delayed GE (right panel), gastric 
retention of the test meal at 2 h and particularly at 4 h is 
increased (normative values were determined from 319 
healthy volunteers; clinically relevant delayed GE is defined 
as a percentage retention >75% at 2 h and >25% at 4 h)30.
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For interpretation of test results, it has to be taken into 
account that clinical utility depends on complete con-
sumption of adequate test meals and adequate duration 
of imaging.
• 13C­gastric emptying breath tests (13C­GEBTs) can be 
used as an alternative to scintigraphy.
Test meals labelled with the stable, nonradioactive iso-
tope 13C can be used to measure gastric emptying. The 
edible blue–green algae, 13C-labelled Spirulina platen­
sis31 or the medium-chain fatty acid, 13C-octanoic acid 
(13C-OA)32, is typically used to label solids; 13C-acetate 
is used for liquids33. On delivery to the duodenum, the 
13C-containing substrate is either absorbed directly 
(13C-OA or 13C-acetate) (FIG. 2) or digested and then 
absorbed (13C-labelled S. platensis). Subsequently, it is 
metabolized, usually in the liver, and finally excreted by 
the lungs as 13CO2. Consequently, 13C-GEBTs are indirect 
tests that involve multiple steps. For 13C-acetate, an inter-
action has been demonstrated between the rate of 13C 
delivery to the duodenum and 13C recovery in breath34. 
Moreover, it has been hypothesized that 13C-GEBTs might 
be inaccurate in conditions associated with substantial 
malabsorption or liver or lung diseases. However, clinical 
studies do not substantiate this assumption35; even in 
patients with liver cirrhosis (~50% Child–Pugh score C), 
13C-OA metabolism was found to be normal36 and the 
13C-OA breath test correlated well with  scintigraphy in 
patients who were critically ill37.
Intraindividual and interindividual variabilities of 
all 13C-GEBTs are high, but they are similar to the vari-
ations observed with scintigraphy4,31,38 and, therefore, 
reflect day-to-day physiological variability in gastric 
emptying. Results of the 13C-labelled S. platensis GEBT 
show a high concordance (r = 0.86) with scintigraphic 
data31, and the test was approved by the FDA for the 
evalu ation of gastric emptying in April 2015. The test kit 
is commercially available (USA only), and the protocol is 
exactly defined and has been validated in a large group 
of healthy volunteers and patients31. For the 13C-OA 
GEBT and the 13C-acetate GEBT, several test protocols 
and multiple mathematical analysis methods have been 
proposed4,32,33,39,40. When using these tests, it is important 
to strictly follow a standardized, validated approach.
• Markedly prolonged retention of the wireless motility 
capsule (WMC) might be a marker of delayed gastric 
emptying.
The WMC (for example, SmartPill, Medtronic, USA) 
is a single-use, orally ingested, non-digestible, data- 
recording capsule that measures pH, pressure and temp-
erature throughout the gastrointestinal tract4. A marked 
increase in pH units is used to estimate gastric emptying 
time (FIG. 3). The WMC has been approved for gastric 
emptying measurements by the FDA and has a CE mark 
for the European Union (complies with the European 
Union safety requirements). However, as the WMC is a 
large, non-digestible, solid object, it does not empty with 
the meal but rather is most often cleared from the stom-
ach by powerful interdigestive (migrating motor complex 
(MMC) phase III) (FIG. 4) antral contractions that occur 
after the meal has been emptied to clear the stomach of 
indigestible material41. Accordingly, passage of the WMC 
into the duodenum correlates only modestly with gas-
tric emptying of nutrients41,42. Emptying of the capsule 
is also delayed in patients with reduced or weak MMC 
phase III contractions. These aspects must be taken into 
 consideration for evaluation of the test.
• Antral or antropyloroduodenal manometry is the 
reference method for evaluation of gastric contraction 
patterns.
Catheter-based manometry with multiple pressure 
sensors located in the antrum, pylorus and duodenum 
is the only clinically available test that enables detailed 
assessment of coordinated gastric contraction patterns3 
(FIG. 4).
Investigation of small bowel motor function
Indications and clinical importance
• Tests of small intestinal motility are indicated in 
patients with suspected severe chronic small bowel 
dysmotility.
Nature Reviews | Gastroenterology & Hepatology
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Figure 2 | 13C-octanoic acid gastric emp ying breath test. The test principle underlying 
the 13C-octanoic acid breath test (part a) is as follows: 13C-octaonoic acid is rapidly 
absorbed after gastric emptying and transported to the liver. Hepatic metabolism leads 
to production and exhalation of 13CO2. Thus, alterations of the 
13C:12C ratio in breath 
samples collected at multiple time points postprandially reflect gastric emptying. 
Examples (part b) of values for accelerated, normal and delayed gastric emptying are 
shown. Normal data (mean ± s.e.m.) are derived from 20 healthy individuals6.
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Even patients with very severe small bowel dysmotility 
fulfilling the diagnostic criteria for chronic intestinal 
pseudo-obstruction (CIPO) have nonspecific symp-
toms such as pain (80%), vomiting (75%), constipation 
(40%) and diarrhoea (20%); this lack of specific symp-
toms has led to misdiagnosis on initial presentation with 
mechani cal bowel obstruction or treatment-refractory 
constipation in 80% of patients43. Severe small bowel 
dysmotility is usually identified by chronic disabling 
gastro intestinal symptoms, which are associated with 
dilatation of some part of the small bowel, with incon-
clusive results of endoscopic and radiological investi-
gations or surgical exploration. It is frequently associated 
with impaired nutritional intake.
• Only those results of intestinal transit tests that 
deviate substantially from normal values are con­
sidered diagnostic of abnormality and indica­
tive of either accelerated or delayed small bowel 
transit.
Small intestinal transit tests are noninvasive, but 
their clinical utility is limited by high interindividual 
and intraindividual variability of small bowel transit in 
healthy individuals (even by as much as >50%)4, which 
leads to a wide normal range. Experts therefore agree 
that only abnormal results, based on recorded tran-
sit times clearly outside normative ranges, should be 
 considered diagnostic.
• Manometric evaluation of small bowel contraction 
patterns should be limited to patients with chronic 
severe and otherwise insufficiently explained 
symptoms or should be used when knowledge of 
small bowel motility disturbances is required for 
management.
Detailed clinical evaluation of antroduodeno jejunal 
contraction patterns by manometry is available in only 
highly specialized centres (FIG. 4). A WMC can also meas-
ure amplitude of antral, small bowel and colonic con-
tractions during its passage through the gastro intestinal 
tract (FIG. 3). Individual antral contractions detected by 
the WMC correlated closely with those observed on 
manometry, and in theory, many of the indications for 
antroduodenojejunal manometry should also apply to 
the WMC3. However, the WMC records pressure at a 
single recording site and cannot appraise propagation of 
contractions. Thus, it is uncertain whether the WMC can 
be a substitute for catheter-based manometric investi-
gation of small bowel motility in terms of  propagation 
of pressure waves.
• Antroduodenojejunal manometry can serve to 
exclude major motility disturbances in patients with 
otherwise equivocal findings.
An entirely normal result in a manometric study 
suggests that motor dysfunction of the upper gastro-
intestinal tract is not a cause of patient symptoms44 and 
that it can differentiate a true motility disorder from a 
somatoform disorder in children45.
• Altered small bowel motility on manometry could 
suggest underlying myopathy or neuropathy. Severe 
motor pattern alterations in combination with docu­
mented episodes mimicking mechanical obstruction 
enable the diagnosis of CIPO.
Myopathic disorders (for example, systemic sclero-
sis, amyloidosis and hollow visceral myopathy) are 
characterized by low-amplitude intestinal contractions 
(<20 mmHg) at affected intestinal sites3. A combination of 
Figure 3 | Example wireless motility recording. Wireless motility 
recordings in a healthy male participant (part a) and a female patient with 
severe constipation (part b) are shown. Gastric emptying in the control 
individual (part a) occurs after ~3 h (upper limit of normal: 5–6 h) and is 
preceded by strong antral contractions suggestive of antral phase III 
motility (red arrow). A constant decrease in pH at ~6 h 30 min (green arrow) 
marks ileocaecal transit, such that small bowel transit time is estimated 
to be ~3 h 30 min (normal range: 2.5–8 h). Abrupt temperature drop 
(blue arrow) shows that the capsule is excreted after ~11 h 30 min, such that 
colonic transit time is ~5 h, which is equivalent to the lower limit of normal. 
In the patient with severe constipation (part b), gastric emptying time is 
relatively long (~5 h, first green arrow), ileocaecal transit occurs ~16 h after 
ingestion of the motility capsule (second green arrow), and excretion of the 
capsule does not occur until 133 h (blue arrow), such that both small bowel 
transit time (~11 h) and colonic transit time (~117 h) are prolonged. Please 
note that the timescales are different for the left and right panels.
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frequent duodenojejunal MMCs (>3 over 3 h) during the 
fasting period, absence of antral MMC phase III, presence 
of postprandial antral hypomotility and a rapid return of 
MMC activity (within 2 h) after a >400 kcal meal suggests 
autonomic neuropathy, typically with vagal dysfunction46. 
Other neuropathic disorders have been associ ated with 
antral hypomotility, abnormal propagation of MMC 
phase III, hypercontractility in the duodeno jejunum 
(phase  III contraction amplitudes >60–100 mmHg 
(P.M.H., unpublished data) and failure to generate the 
fed response3. However, studies comparing manometric 
and histological findings are weak, and in the absence of 
a gold standard, the sensitivity and specificity of mano-
metry abnormalities for differentiating causes of motility 
diseases have not been extensively evaluated.
For the identification of manometric patterns that 
predict obstruction, manometry has been compared 
with the results of laparotomy47. A study published in 
1994 confirmed that non-propagated clustered contrac-
tions (>30 min duration) and simultaneous prolonged 
(>8 s) or summated contractions suggest mechani-
cal obstruction even when this finding is equivocal 
on  barium small bowel radiography47. However, with 
modern and more-sensitive imaging techniques such 
as CT enterography or magnetic resonance entero clysis, 
manometry is seldom required for this indication in 
clinical practice.
CIPO is a rare disease in which severe intestinal 
dysmotility impairs transit of chyme such that patients 
present with signs of subileus and ileus on imaging 
without mechanical obstruction48,49. Small intestinal 
manometry permits diagnosis of severe intestinal motil-
ity disturbances compatible with CIPO50 even during 
mostly asymptomatic intervals. Moreover, manometry 
can be used to determine which organs need to be trans-
planted (isolated versus multi visceral  transplantation) 
in patients failing all other treatment options3.
Additional indications for small bowel manometry 
include detection of retrograde propagated contrac-
tions, for instance, after Roux-en-Y gastric surgery51, 
and exclusion of generalized dysmotility in patients 
with colonic inertia before subtotal colectomy. This 
step is relevant because patients with additional upper 
gastrointestinal motor abnormalities have a worse long-
term outcome after surgery52. Whereas small bowel 
manometry can confirm a diagnosis of rumination syn-
drome3, high-resolution oesophageal manometry with 
 impedance1,53 is now preferred for this indication.
Recommended diagnostic approaches
• Scintigraphy is the reference method for evaluation 
of small bowel transit time.
Scintigraphic assessment of small bowel transit time is 
usually performed as part of a whole-gut transit study4. 
Scintigraphy directly visualizes passage of the radio-
active marker throughout the small bowel and provides 
physiological and quantitative data. However, the tech-
nique is not standardized, has wide normal ranges and 
is rarely performed outside the USA.
Figure 4 | Example plots of high-resolution gastroduodenal manometry. High-resolution gastroduodenal manometry 
plots are shown for normal fasting (part a) and postprandial (part b) motility. Antral motility is characterized by 
high-amplitude contractions with a maximal contraction rate of ~3 per min. Amplitudes of contraction in the small bowel 
are lower, but frequency is higher (up to ~12 per min). During the fasting state (part a), there is a constant transition 
between phases I to III of the interdigestive migrating motor complex (MMC) with motor quiescence during phase I, 
irregular contractions that are propagated over only smaller segments during phase II and regular, aborally propagated 
contractions that usually start in the stomach and traverse long segments of the small bowel during phase III. 
Postprandially (part b), MMC activity is interrupted and replaced by irregular contractions that serve to mix the luminal 
contents and to slowly propel them towards the more distal intestine. Desc., descending; Prox., proximal.
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• The WMC can be used to measure small bowel transit.
The WMC uses pH landmarks to identify passage 
through the pylorus and through the ileocaecal junction 
for calculation of small bowel transit time (FIG. 3). A small 
study of ten healthy adults who underwent WMC and 
scintigraphy simultaneously demonstrated a moderate 
correlation between the two methods (r = 0.69, P = 0.05)54, 
but validation studies for the WMC have mostly concen-
trated on whole-gut transit time, gastric emptying time 
or colonic transit time. Moreover, in a large study of 215 
healthy volunteers published in 2015, the ileocaecal junc-
tion could not be clearly identified by WMC based on pH 
patterns in >10% of healthy individuals, and the agree-
ment between automated software analysis and manual 
reading was much lower for small bowel transit time than 
for any other regional or whole-gut transit time55.
• The lactulose H2 breath test (LHBT) is an inexpensive 
and noninvasive but less precise alternative marker of 
small bowel transit.
The LHBT is a semi-quantitative test that measures 
orocaecal transit time using the increase in H2 exhalation 
associated with caecal delivery and subsequent bacterial 
metabolism of the nonabsorbable saccharide lactulose56,57 
(FIG. 5). The test can be easily performed and is widely 
available, inexpensive and not associated with radiation 
exposure58. However, lactulose is not an inert marker; 
it can accelerate orocaecal transit time through osmotic 
fluxes into the small intestine59, and it also delays gas-
tric emptying time60. Moreover, misleading results with 
falsely short transit times are to be expected in patients 
with small intestinal bacterial overgrowth, which is 
particularly problematic because small bowel motility 
disturbances can cause this condition61,62.
Moreover, the LHBT does not specifically measure 
small bowel transit time; rather, it reflects the summation 
of gastric and small bowel transit. Gastric emptying of 
the liquid test solution occurs rapidly and might be neg-
ligible in healthy individuals. However, in patients with 
gastrointestinal motility disturbances, gastric emptying 
may markedly influence the measured orocaecal transit 
time. This problem could be overcome by combining the 
LHBT and the 13C-acetate GEBT such that small bowel 
transit time can be calculated as the difference between 
orocaecal transit time and the gastric emptying time63.
• Small bowel manometry is the reference method for 
evaluation of intestinal contractile patterns.
Catheter-based manometry with multiple pressure 
sensors permits detailed assessment of small bowel con-
traction patterns3 (FIG. 4). Manometry sensors are usually 
placed in only the proximal small bowel (duodenum and 
proximal jejunum) for practical reasons, and tracings 
from these segments are assumed to reflect motility 
of the total small intestine3, although this aspect has 
not been tested rigorously. Ambulatory investigations 
are performed over 24 h by some centres, while other 
 centres perform stationary manometry with recordings 
over 3–4 h in the fasting state and for an additional 2 h 
after ingestion of a test meal3. Manometry can reveal 
low-amplitude contractions or disorganized contractile 
patterns or normal amplitudes, frequencies and patterns 
of  contractions3 (FIG. 4).
Investigation of colonic motor function
Indications and clinical importance
• Severe constipation refractory to conventional treat­
ment and not explained by common imaging tech­
niques is the main indication for colonic motor 
function testing. Certain measurements of colonic 
motility might provide useful information in a subset 
of patients with diarrhoea.
Severe colonic dysmotility usually impairs propaga-
tion of luminal contents and is consequently associated 
with slow-transit constipation. In a subset of patients 
with diarrhoea, relevant alterations of colonic motility 
can be identified, for example, increased frequency of 
high amplitude propagated contractions during the day 
and/or after a meal3. Moreover, colonic scintigraphy or 
radio paque marker (ROM) transit has been shown to 
differ between subtypes of functional disorders of the 
lower gastrointestinal tract and healthy individuals64,65. 
Transit was generally accelerated in diarrhoea and 
delayed in constipation, confirming that motor dysfunc-
tion is of pathophysiological importance. Thus, colonic 
transit measurement could identify subgroups more 
likely to respond to treatment directed at dysmotility.
• Evacuation disorders should be excluded as a potential 
cause of constipation symptoms before  intraluminal 
tests of colonic motility are considered.
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Figure 5 | Lactulose H2 breath test for measurement of orocaecal transit time. 
Representative lactulose H2 breath tests (LHBTs) are shown for accelerated (30 min), 
normal (75 min) and delayed (225 min) orocaecal transit times (OCTTs). The test requires 
H2 measurements at regular intervals after ingestion of lactulose. H2 values of >10 ppm 
over basal values followed by at least two subsequent increments (arrows) indicate 
caecal delivery of the nonabsorbable substrate with subsequent bacterial metabolism. 
This increase in H2 exhalation normally occurs 50–200 min after ingestion of the marker 
substance (normal range for OCTT marked in grey).
C O N S E N S U S  S TAT E M E N T
298 | MAY 2018 | VOLUME 15 www.nature.com/nrgastro
©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved. ©
 
2018
 
Mac mill an
 
Publishers
 
Li mited,
 
part
 
of
 
Spri nger
 
Nature.
 
All
 
ri ghts
 
reserved.
A meta-analysis published in 2013 suggested that 
~50% of patients with chronic constipation have dys-
synergic defecation according to anorectal mano metry66. 
In comparison, ~60% of patients with dyssynergic defe-
cation have delayed colonic transit67, which can be 
secondary to the evacuation disorder. Colonic transit 
could accelerate, and symptoms can improve or even 
resolve with treatment of the evacuation disorder68,69. 
Thus, delayed colonic transit does not necessarily reflect 
colonic inertia and does not imply a colonic motility dis-
order as the sole cause of constipation. Moreover, anato-
mical alterations such as large rectoceles or mucosal 
prolapse can impair stool evacuation. Both dyssynergic 
defecation70 and anatomical alterations require specific 
treatments and should be identified before elaborate 
investigation of colonic motility.
• Colonic transit tests are required to distinguish  normal 
from slow­transit constipation.
Clinical markers do not predict slow-transit consti-
pation reliably. In particular, stool frequency is a poor 
surrogate for transit even in those with reduced stool 
frequency71,72. Hard stool (form 1 or 2 on the Bristol 
Stool Chart) predicts delayed versus normal transit, but 
only a moderate correlation exists between stool form 
and whole-gut or colonic transit time in adults with con-
stipation71. Moreover, normal-transit constipation has 
been observed in >70% of patients with constipation- 
predominant IBS (IBS-C) or functional constipation64,73. 
In ~5% of patients, colonic transit was even accelerated. 
Vice versa, a subset of patients with IBS with diarrhoea 
(IBS-D) had delayed colonic transit64,73. Transit tests are, 
therefore, required to identify slow colonic transit and 
can optimize the choice of treatment74.
• Colonic scintigraphy and ROM can provide initial 
information to differentiate between diffuse and 
localized colonic dysmotility and/or evacuation dis­
orders. However, transit measurements alone are 
not diagnostic of evacuation disorders and require 
 confirmation by specialized tests of evacuation.
Regional scintigraphic transit profiles and distrib-
ution of ROM can give initial information on the patho-
physiology of constipation4,75–77. Retention of ROM in 
the entire colon is expected in slow-transit constipation 
(FIG. 6), whereas concentration of ROM in the recto-
sigmoid suggests an evacuation disorder. Accordingly, 
transit tests can help direct treatment: if overall transit 
is delayed, prokinetic treatment might be indicated; 
if overall transit is normal, patient education, diet-
ary advice and/or osmotic laxatives usually suffice. 
If dyssynergic defecation is present, biofeedback train-
ing is indicated70,78. However, transit can be slow in dis-
orders of rectal evacuation, such that specialized tests 
such as anorectal manometry, the balloon evacuation 
test or defaecography are required to confirm func-
tional or structural causes of evacuatory dysfunction67. 
Moreover, even if transit tests suggest that a specific seg-
ment of the colon is responsible for delayed transit, in the 
absence of localized megacolon, experts advise against 
segmental colonic resection in  treatment-refractory 
slow-transit constipation79.
• Invasive therapeutic measures for severe consti­
pation, that is, subtotal colectomy, require proof of 
colonic dysmotility. In such patients, colonic transit 
tests are mandatory. Tests of colonic contractility are 
desirable, including measurement of colonic tone or 
compliance in some cases.
International guidelines agree that subtotal colectomy 
for treatment of chronic constipation is indicated in only 
patients with severe disease who are refractory to con-
servative treatment49,80,81. Proof of colonic dys motility is 
a prerequisite. In patients with slow-transit constipation 
as documented by transit tests, multiple failed thera-
peutic trials are used by many centres as an indication 
for subtotal colectomy3. In other centres, a diagnosis 
of colonic inertia on the basis of colonic contractility 
testing (FIGS 7,8) is required before sub total colectomy 
because some patients with slow-transit constipation 
have normal colonic contractility, tone and compliance 
and normal responses to pharmacological stimulation 
with intraluminal bisacodyl or intra venous neostig-
mine according to barostat manometry3. Major upper 
Nature Reviews | Gastroenterology & HepatologyFigure 6 | Assessment of colonic transit time with 
radiopaque markers. A radiopaque marker test of a 
patient who ingested 10 markers every morning for 6 days 
is shown. The plain abdominal radiograph was taken 
on day 7 and shows that all 60 markers are retained; 
accordingly, colonic transit time is ≥144 h ((number of 
retained capsules × 24 h)/(number of capsules ingested per 
day)). Normal values include colonic transit times ≤70 h in a 
mixed population, ≤50 h in men and ≤70–106 h in women. 
Note that in this case, the markers are evenly distributed 
throughout the colon, which is regarded as typical of, but is 
not completely specific for, slow-transit constipation.
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gastrointestinal motility disturbances negatively influ-
ence the therapeutic outcomes of patients under-
going colectomy52,82 and should therefore be excluded. 
As shown by a small but rigorous study in 18 children, 
high-resolution colonic manometry might be able to 
identify underlying neuro pathy as suggested by the 
absence of motor quiescence between bisacodyl-induced 
high-amplitude propagating contractions; this finding 
was associated with histologically proven neuropathy 
(positive predictive value 92%; negative predictive value 
100%)83. Another study using conventional manometry 
was unable to classify specific mano metric findings as 
reflective of myopathic or neuropathic abnormalities in 
patients with colonic motility disorders84. Future stud-
ies are required to confirm whether high- resolution 
manometry findings can be used to  differentiate 
 aetiologies of colonic motility disorders.
• Measurement of compliance and tone by barostat con­
firms overt megacolon identified radiologically and 
can identify less­severe cases of chronic megacolon.
The characteristic feature of chronic megacolon on 
barostat measurements is an excessively high fasting 
volume (FIG. 8), which suggests low colonic tone85, and 
a markedly increased colonic compliance. A colonic 
balloon volume >300 ml at a distension pressure 
of 20 mmHg was found to be virtually diagnostic of 
chronic mega colon, such that this measure can be used 
for diagnostic purposes in patients with clinical suspi-
cion of chronic megacolon or when the imaging studies 
are equivocal. The same observations are also pertinent 
in syndromic megacolon and in multiple endocrine 
 neoplasia type 2B syndrome86.
Recommended diagnostic approaches
• ROM studies and colonic scintigraphy are best suited 
for measurement of colonic transit time.
Scintigraphy can evaluate both regional and overall 
colonic transit, and depending on the method used, 
it can be performed as part of a whole-gut transit study 
over 48 h or 72 h, incorporating assessment of gastric and 
Figure 7 | Example colonic high-resolution manometry. Colonic high-resolution manometry recordings in a healthy 
individual (part a) and a patient with slow-transit constipation (part b) are shown. Note the physiological increase in colonic 
contractility that occurs within minutes after the test meal. In the patient with slow-transit constipation, the frequency and 
amplitudes of colonic contractions are markedly reduced and the motor response to feeding is virtually absent.
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small bowel transit also4. This method provides accur-
ate and quantitative results for colonic transit time but 
requires highly specialized personnel, is expensive and 
has limited availability.
ROM studies, on the other hand, can be performed 
easily and are inexpensive and widely available but are 
less well standardized across centres, and the avail-
ability of quantitative results depends on the technique 
chosen. Colonic transit time can be quantified after an 
equilibrium between daily marker output and input has 
been achieved87, which requires ingestion of radiopaque 
markers and obtaining an abdominal radiograph at 
speci fied times. Several validated variations are avail-
able. One approach involves ingestion of 20 markers 
on day 1 and counting the remaining markers on day 5, 
with >5 remaining markers implying delayed transit88,89. 
In other variations of the ROM test, a fixed  number 
of ROMs are ingested over several days (for example, 
24 markers on days 1–3) with abdominal radiography 
on the following day75. Other established protocols 
use marker ingestion for 4 days, or preferably, 6 days87; 
accordingly, radio graphy is performed on either day 5 
or day 7 (FIG. 6). Patients need to abstain from laxatives 
for 2 days before and throughout the test. Thus, the long 
duration of the test hampers compliance, particularly 
in patients with severe symptoms. Still, decreasing the 
duration of the testing period is hardly sensible because 
in mixed populations, mean colonic transit time is 
30–40 h with an upper limit of normal of 70 h (REF. 4). 
In women, a colonic transit time of up to 106 h has been 
reported to be normal90.
• The WMC can be used as an alternative to assess 
overall (though not regional) colonic transit.
To calculate the colonic transit time, the WMC uses 
pH pattern and temperature drop or loss of signal to 
determine ileocaecal passage and evacuation of the 
capsule, respectively (FIG. 3). Large studies have shown 
good agreement between the WMC and ROM or scinti-
graphic studies54,91,92. Accordingly, the technique is FDA 
approved for the evaluation of colonic transit time in 
patients with chronic idiopathic constipation93.
• Colonic manometry (preferably of high resolution) 
is the reference method for evaluation of colonic 
 contractile patterns.
Colonic motor activity is characterized by phasic or 
brief contractions and tonic or sustained contractions. 
Only the former can be assessed adequately by mano-
metry (FIG. 7). Stationary laboratory-based mano metric 
studies conducted for up to 6 h record fasting and post-
prandial phasic contractions, as well as colonic tone 
and compliance, when a barostat assembly is used in 
addition to manometry (FIG. 8). Ambulatory 24 h studies 
usually measure only phasic contractions3. Conventional 
manometry has identified isolated pressure waves, 
propa gated low-amplitude and high-amplitude pressure 
waves (the latter (>75–116 mmHg) being of particu lar 
importance for movement of contents across the colon), 
simultaneous pressure waves (associated with neuro-
pathy in children but not in adults), retrograde pressure 
waves and periodic colonic and rectal motor activity with 
bursts of phasic and tonic pressure waves3,94. However, 
it has been shown that high-resolution manometry 
with closely spaced pressure recording sites <2 cm apart 
are mandatory to avoid gross misrepresentation of the 
frequency, morphology and  directionality of colonic 
 propagating sequences95.
• A barostat enables the assessment of colonic 
 compliance, tone and phasic contractility.
The assessment of colonic compliance and tone 
requires a barostat device with a balloon placed into the 
Figure 8 | Assessment of colonic tone using a barostat device. The barostat balloon is placed into the colon 
endoscopically (part a). The barostat device keeps intraballoon pressure at a pre-set level chosen to ensure apposition 
of the balloon to the colonic wall without relevant distension. Phasic and tonic contractions therefore induce a decrease 
in baseline balloon volume. The panels show phasic and tonic contractile activity measured under constant pressure 
conditions in the colon of a patient with slow-transit constipation (part b) and in the colon of a patient with chronic 
megacolon (part c). Note the large colonic volume (indicating low tone) during fasting in part c and the persistence 
of phasic contractile activity despite the low colonic tone.
a
c
b
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Table 1 | Complementary tests of gastrointestinal motor function available* or in development
Test Principle Performance Advantages, disadvantages and 
miscellaneous
MRI136–145 Ingestion of (liquid) meal; 
information on gastric volume, 
secretion, emptying and 
contractions can be derived from 
repetitive scans, information on 
OCTT and CTT with prolonged 
measurements possible
• Test meal usually labelled with gadolinium; 3D 
volume scan (‘static’) for evaluation of gastric 
emptying, fast (‘dynamic’) 2D scan to assess 
gastric, small bowel and colonic motility
• OCTT represented by arrival of head of meal 
in caecum
• Advantages: noninvasive, 
simultaneous information on different 
physiological aspects (for example, 
secretion and emptying)
• Disadvantages: time consuming, 
expensive
• Miscellaneous: preliminary data 
suggest that it can detect colonic 
high-amplitude contractions
Gastric 
barostat146–148
Computer-controlled pump 
controls volume or pressure in 
large non-compliant bag (>700 ml) 
placed in fundus via nasogastric 
catheter; measurements of gastric 
compliance and/or distensibility 
and sensitivity in response to 
distension stimulus or meal are 
possible
• Volume change in response to applied pressure 
or pressure change in response to applied 
volume (or a meal) is monitored to assess gastric 
relaxation (accommodation) and contraction; 
concurrent grading of subjective symptoms  
and/or sensitivity (gastric hypersensitivity in 
40% of patients with dyspepsia)
• Gastric relaxation documented after meal or 
nutrient infusion (accommodation impaired 
in 40% of patients with dyspepsia)
• Advantages: best validated method 
for gastric tone and sensation
• Disadvantages: invasive, can cause 
physical and psychological distress
• Miscellaneous: MRI and, potentially, 
other imaging modalities provide 
indirect, noninvasive assessment 
of gastric volumes
Abdominal 
ultra sono-
graphy149
• 2D: ultrasonography; indirect 
measurement of gastric emptying 
by quantifying changes in antral 
cross-sectional area or diameter
• 3D: scanning of entire stomach 
by continuous translational 
movement along its long axis 
and transverse sections of entire 
stomach; computer-assisted 
3D-reconstruction
• Ingestion of liquid test meal; sonography at 
regular intervals for prolonged period (for 
example, at 15 min intervals for 3 h)
• 2D: 50% emptying time = time when antral area 
has decreased to half of its maximum
• 3D: 50% emptying time = time when gastric 
volume has decreased to 50% of that immediately 
after meal intake
• Advantages: noninvasive
• Disadvantages: time consuming and 
not standardized; 2D offers no good 
representation of meal distribution in 
stomach
Proximal 
gastric 
HRM150,151
Pressure drop in the proximal 
stomach after application of 
nutrients is used as a measure of 
gastric accommodation
Transnasal placement of HRM catheter in the 
(proximal) stomach; registration of pressure for a 
prolonged period of time
• Advantages: generally available owing 
to dissemination of oesophageal HRM
• Disadvantages: invasive and has 
limited normative data and use to date 
(studies ongoing)
Impedance 
planimetry 
for functional 
lumen 
imaging152–154
Transnasally or transorally 
positioned probe with 16 serial 
impedance electrodes enclosed 
in a high-compliance bag and a 
solid-state pressure transducer
Probe is positioned (via endoscopy and/or  
fluoroscopy) so as to straddle the pylorus; 
the balloon is then inflated while diameter, 
cross-sectional area and pressure are measured, 
allowing calculation of distensibility (by dividing 
cross-sectional area by pressure at a specific 
balloon volume)
• Advantages: direct measurement 
of pyloric distensibility; can identify 
phenotypes not otherwise identified; 
can be combined with endoscopy
• Disadvantages: invasive and not 
widely available; limited normative 
data; uncertain clinical utility
Cutaneous 
electrogastro-
graphy106,107
Myoelectric signal at ~3 cpm 
waveform frequency is normal; 
signal amplitude (‘power’) 
increases after meals; loss or 
damage of interstitial cells of Cajal 
that generate and propagate slow 
waves occurs in disease, which is 
thought to result in arrhythmias 
and loss of power
Placement of 3 electrodes in a supine or up to 
45° reclined position: recognizable waveforms 
should be visually identifiable in >15 min (fasting) 
or >30 min (post-meal); in health, 3 cpm rhythm 
present ≥70% of the time, with increase in power 
after meals; in tachygastria, >3 cpm present >30% 
of the time; in bradygastria, <3 cpm present >30% 
of the time; nonspecific dysrhythmia (absence of a 
single predominant rhythm), lack of motor response 
to meal and >20% total power in the tachygastria 
range are also considered abnormal
• Advantages: noninvasive
• Disadvantages: summative nature 
of recordings; poor signal–noise ratio; 
lack of sensitivity and specificity; 
validity of technique not confirmed by 
comparison with direct measurements 
of gastric contractility or emptying 
and not widely available
• Miscellaneous: high-resolution 
electrogastrography mapping from 
stomach promising
SPECT96–98 Imaging of the gastric wall using 
intravenous 99mTc pertechnetate 
with noninvasive SPECT and 3D 
image analysis
99mTc pertechnetate is taken up and excreted by 
gastric mucosa; images acquired by gamma camera 
are reconstructed to produce a 3D representation 
of the entire gastric volume; predominantly used for 
evaluation of gastric accommodation
• Advantages: noninvasive
• Disadvantages: available at only 
a few centres
• Miscellaneous: can be used to assess 
drug effects
Endoluminal 
image 
analysis155–158
Computerized analysis of small 
bowel images obtained by the 
endoscopic capsule
• Ingestion of endoscopic capsule after overnight 
fast; ingestion of 300 ml liquid meal (1 kcal per ml) 
45 min after gastric evacuation
• A combination of parameters reflecting wall 
dynamics and movement of content are used to 
automatically discriminate normal and abnormal 
intestinal motor function, which provides further 
discrimination between hypodynamic and 
hyperdynamic motor disorders
• Advantages: noninvasive technique, 
operator-independent and higher 
sensitivity than intestinal manometry
• Disadvantages: restricted to research 
and requires further validation
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colon endoscopically (FIG. 8). The barostat keeps intra-
balloon pressure at a pre-set level chosen to ensure appo-
sition of the balloon to the colonic wall without relevant 
distension. Changes in baseline balloon volume thus 
reflect changes in colonic tone3. Because the barostat 
can detect phasic contractions that are non- lumen 
occluding, this technique is also more accurate than 
manometry for detecting phasic contractions when the 
colonic diameter is increased (>5.6 cm)3 (FIG. 8). Colonic 
compliance is a measure of the ease with which the 
colon can be distended and can be evaluated by record-
ing changes of balloon volume in response to stepwise 
(usually 4 mmHg) increments of intraballoon pressure 
to 44 mmHg.
The physiological increase in colonic tone in response 
to a standard meal has been well characterized and  varies 
among the segments of the colon. In the descending 
colon, a <15% increase in tone after a meal suggests a 
relevant colonic motility disorder3.
Additional tests
Tests of neuromuscular function and structures
• The clinical utility of the tests specified in Table 1 is 
limited or subject to ongoing studies.
Additional tests for assessing gastrointestinal motil-
ity have been proposed (TABLE 1) and are the subject 
of ongoing study or are available at a few centres. For 
example, gastric mucosal labelling with single-photon 
emission CT (SPECT) imaging can measure gastric 
volumes and accommodation. SPECT has been well 
valid ated96–98 and used in thousands of patients in select 
clinics but is still not widely available. Similar informa-
tion on gastric motor functions can be obtained by MRI 
(TABLE 1).
• Limited data on the amplitude of gastrointestinal 
contractions can be obtained using a WMC.
Apart from pH and temperature, the WMC also 
records pressure throughout the gastrointestinal tract. 
However, with a single pressure recording port that 
traverses the gastrointestinal tract, the WMC cannot 
identify physiological or pathological motor patterns, 
which are essential for diagnosing neuropathic gastro-
intestinal motility disturbances (discussed  earlier). 
Nevertheless, limited data on the amplitude of gastro-
intestinal contractions can be obtained by a WMC 
(FIG. 3), and the presence (though not the propaga-
tion) of MMC phase III events can be detected with 
reasonable sensitivity99.
• In selected cases with severe disease, full­thickness 
biopsy could be useful for therapeutic decisions.
Conventional mucosal biopsy samples obtained 
endoscopically do not contain relevant muscular and 
neuronal structures, in particular, they lack the muscu-
laris propria and the myenteric plexus. Thus, gastro-
intestinal neuromuscular disturbances, including 
those affecting the interstitial cell of Cajal (ICC), can 
be diagnosed histologically using only full- thickness 
biopsy samples that are usually obtained surgically. 
Because of the invasiveness of the procedure, histo-
logical investi gations are limited to patients with 
severe disease (unless full-thickness biopsy samples 
are available from previous surgery). Moreover, clin-
ically rele vant information can only be obtained with 
expert evaluation. The London Classification100 classi-
fies gastro intestinal neuromuscular pathology on the 
basis of defined histopathological criteria derived from 
previous guidelines and presents indications, recom-
mendations for safe acquisition of tissue, histological 
techniques and reporting and referral guidelines. Data 
on the ICC and other enteric system markers from a 
cohort of patients with gastroparesis and nondiabetic 
control patients under going bariatric surgery can help 
provide normative values for research and clinical 
use101. Certain histopathological findings, such as ICC 
loss, were found to correlate with gastric emptying rates 
in diabetic gastroparesis102, and other disorders, such 
as enteric ganglionitis or myositis, can be the rationale 
for immuno suppressive treatment103. For the stomach, 
there are only preliminary data suggesting that histo-
logical findings can guide treatment104. An  endo-
scopic method to obtain myenteric plexus samples for 
 histopathological assessment has been described105.
Other emerging technologies
Although the techniques described earlier are used to 
measure gastrointestinal transit and contractility or 
to assess morphological alterations of neuro muscular 
Table 1 (cont.) | Complementary tests of gastrointestinal motor function available* or in development
Test Principle Performance Advantages, disadvantages and 
miscellaneous
Magnetic 
pill159,160
Small magnet is ingested and 
tracked by external matrix of 
magnetic field sensors; can detect 
movements of capsule induced by 
contractions; change in dominant 
contraction frequency used to 
define segmental gastrointestinal 
transit times
• Stationary system: 16 external sensors used 
(4 × 4) giving a position defined by 5 coordinates 
(positions x, y and z and angles θ and φ
• Ambulatory system now trialled, using 4 sensors 
contained within an extracorporeal portable 
detector plate
• Dominant frequency of 3 contractions per min in 
stomach changes to 10 contractions per min when 
magnetic pill enters small intestine and drops to 
4–5 contractions per min with ileocaecal passage
• Advantages: noninvasive
• Disadvantages: restricted to research 
and requires further validation and 
software development
cpm, cycles per minutes; CTT, colonic transit time; HRM, high-resolution manometry; OCTT, orocaecal transit time; SPECT, single-photon emission CT. *At a few 
specialist centres.
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structures of the gastrointestinal tract, there are other 
emerging techniques that will probably add valuable 
information on the classification of gastrointestinal 
motor disturbances in the future. These techniques 
concentrate on electrophysiology, release of neuro-
hormonal trans mitters from the mucosa, auto immune 
and  inflammatory  markers and measurement of 
autonomic function.
High-resolution electrical mapping. The myo-
electric signal of the stomach can be investigated non-
invasively using cutaneous electrogastrography (cEGG, 
TABLE 1)106,107. The cEGG profile is disturbed in gastro-
paresis, probably owing to loss or dysfunction of ICCs. 
In fact, cEGG has been used clinically for decades and 
has demonstrated associations between arrhythmias 
and gastroparesis. However, it is fundamentally limited 
by its summative nature, low signal quality and incom-
plete sensitivity and specificity106–108. High-resolution 
electrical mapping has emerged and involves electrodes 
placed on the stomach at laparo scopy. This technique 
provides superior spatial data on arrhythmic patterns 
and mechanisms and has revealed the surprising 
complexity of gastric arrhythmias108. Dysrhythmias 
include abnormalities of initiation ( stable ectopic 
pacemakers and unstable focal activities) and con-
duction (retrograde propagation, wavefront collisions, 
conduction blocks and re-entry) and operate across 
bradygastric, normal and tachygastric frequencies108. 
Studies in small groups of patients with functional 
nausea and vomiting or gastroparesis identified slow-
wave dysrhythmias in all but one participant109,110. 
Arrhythmias were similar in both patient groups, 
indicating that they could be spectra of the same dis-
order109. To date, the clinical use of high-resolution 
mapping is hampered by its invasiveness because it 
requires general anaesthesia and laparoscopy; however, 
minimally invasive  intraluminal electrical mapping is 
under development.
Biomarkers. Both functional gastrointestinal diseases 
and defined gastrointestinal motor disorders such as 
gastroparesis and CIPO can occur after infections1,2,111. 
Evidence is accumulating that the pathophysiology in 
these patients is driven by impaired intestinal barrier 
function, which could cause low-grade mucosal inflam-
mation associated with altered control of or damage to 
the enteric nervous system112–116. These new data are an 
intriguing and promising field of research. However, 
there are so far no clinically established mucosal or 
systemic markers that enable prediction or diagnosis of 
neuronal dysfunction or loss.
Autoimmune mechanisms. In another subset of 
patients with gastrointestinal motor disorders, auto-
immune mechanisms have been described that lead 
to impairment of neuromuscular structures and/or 
function. For example, enteric ganglionitis and subse-
quent destruction of enteric neurons in paraneoplastic 
CIPO are frequently associated with anti-Hu anti-
bodies directed against nuclear structures of neuronal 
cells117,118. Antibodies against neuronal voltage-gated 
calcium and potassium channels, antibodies against 
the acetylcholine receptor, other neural autoanti-
bodies and other antibody markers of organ-specific 
autoimmunity ( thyroid or gastric parietal cell specifi-
cities) have also been described in patients with 
autoimmune dysmotility118.
Autonomic dysfunction. Autonomic dysfunction is 
another important cause of major gastrointestinal 
motor disorders. For example, diabetic gastroparesis is 
largely attributed to autonomic neuropathy, although 
several other pathophysiological mechanisms, in par-
ticular, loss of ICCs, contribute to the impairment 
of motor function9,101. In one study, more patients 
with autonomic dysfunction appear to have rapid 
rather than delayed gastric emptying as a potential 
cause of gastro intestinal symptoms119. Heart rate vari-
ability measure ments have been used successfully for 
diagnosis of autonomic neuropathy and represent a 
non invasive, complementary tool to conventional auto-
nomic testing in the clinic120,121. Research has revealed 
that autonomic dysfunction can also be caused by 
auto immune mechanisms. Autoimmune autonomic 
ganglio nopathy is a disorder of isolated autonomic fail-
ure associated with antibodies to the nicotinic acetyl-
choline receptor of the autonomic ganglia, which 
results in severe orthostatic intolerance, syncope, con-
stipation, gastro paresis, urin ary retention, dry mouth, 
dry eyes, blurred vision and anhidrosis122. Patients with 
higher antibody titres have wide spread dysautonomia, 
whereas those with lower antibody levels can present 
with, or evolve into, more focal or restricted presenta-
tions122. Moreover, in patients with autoimmune dys-
autonomia and gastroparesis, antibodies to glutamic 
acid decarboxy lase have been described104. Importantly, 
immunomodulatory therapy improved symptoms in a 
small number of patients positive for antibodies against 
glutamic acid decarboxy lase who had been refractory 
to approved drug and device therapies104. Thus, some 
emerging diagnostic  techniques could establish new 
therapeutic options.
General considerations
• Adherence to standardized and adequately validated 
study protocols is necessary.
Standardized study protocols validated in a large 
 number of healthy individuals and patients are only 
available for some motility tests. For instance, WMC 
testing in clinical practice follows a fixed protocol 
that involves ingestion of the WMC immediately after 
consumption of a defined test meal (260 kcal nutrient 
bar), a 6 h interval before ingestion of the next meal, 
avoidance of strenuous or vigorous exercise and return 
of the data receiver after 5 days93. For scintigraphic 
evaluation of transit times and 13C-labelled S. platensis 
GEBT, well-validated protocols are also available31. For 
many of the other tests, there are various test protocols, 
and validation has frequently been performed in a low 
 number of individuals.
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• Patient preparation for testing of gastrointestinal 
motor function usually requires overnight or pro­
longed fast and avoidance of medications that affect 
gastrointestinal motility.
Under physiological circumstances, motor patterns of 
the entire gastrointestinal tract rapidly adapt to food 
intake. For instance, within minutes after the start of a 
meal, the proximal stomach accommodates, small bowel 
motility changes from the cyclic interdigestive to the fed 
pattern (FIG. 4), and colonic phasic and tonic contractions 
increase (FIGS 7,8). The extent and duration of motility 
changes depend on caloric content and composition of 
a meal. Thus, to enable standardization, it is essential 
that patients have been fasting for a sufficient length of 
time. Furthermore, for tests requiring gastric or intesti-
nal catheter placement, the risk of aspiration is reduced 
by fasting.
To assess an underlying intrinsic motor dis order, 
avoidance of medications that affect gastrointestinal 
motility is required, particularly prokinetic agents, 
opioids, tricyclic antidepressants and laxatives. The 
dur ation of withdrawal depends on the half-life of 
the drug, but usually, 48–72 h are sufficient. Not with-
standing the above guidelines, it might be necessary 
to perform motility tests despite ongoing medication 
if essential long-term medication is concerned or if 
the effect of the drug on gastrointestinal motility is to 
be determined.
• For gastric emptying testing, fasting blood glucose 
should be reasonably well controlled.
A blood glucose concentration >288 mg per dl 
(16 mmol per l) markedly delays gastric emptying in 
patients with diabetes when compared with euglycae-
mia123. Thus, it is generally recommended that fasting 
blood glucose should be <275 mg per dl (15 mmol 
per l) on the study day. Otherwise, delayed gastric 
emptying owing to neuromuscular disturbances, for 
example, diabetic autonomic neuropathy, cannot be 
distinguished from the effects of hyperglycaemia. Some 
experts recommend lower thresholds (<180 mg per dl 
(10 mmol per l))24.
• Other factors such as use of medications known 
to influence gastrointestinal motility (for exam­
ple, prokinetics, opioids, tricyclic antidepressants, 
laxatives and others), prior surgery (for example, 
fundoplication, some forms of bariatric surgery or 
intestinal resections) and drug abuse (for example, 
of opioids or cannabinoids) should be detailed in the 
clinical history and considered when interpreting 
test results.
Although it is not always possible or  reasonable 
to avoid medications known to influence motility 
(as already discussed), it is mandatory to consider 
potential confounders when interpreting test results, for 
example, the abuse of opioids124–128 or cannabinoids129,130 
or prior fundoplication131.
• Behavioural conditions such as rumination syndrome 
or eating disorders should be considered as a cause 
of symptoms.
Rumination syndrome with apparently effortless 
regurgitation of gastric contents into the mouth, caused 
by contractions of the abdominal wall with subse-
quent re-swallowing or spitting1, is a relevant differ-
ential diagnosis in patients who report vomiting and 
regurgitation. Typically, these patients do not respond 
to conventional therapy. Eating disorders can be mis-
interpreted as gastro paresis but can also be associated 
with  gastrointestinal motility disorders132.
• There is a marked and unclear overlap in symptoms 
between patients with gastrointestinal dysmotility 
and patients with functional gastrointestinal dis­
orders, in whom altered motility is thought to be one 
among several pathophysiological mechanisms.
Substantial overlap exists in symptoms between gas-
tro paresis and functional dyspepsia and between enteric 
(including colonic) dysmotility and IBS or functional 
constipation13,133. All functional gastro intestinal diseases 
are associated with some degree of motor disorder in the 
gastrointestinal tract. Delayed gastric emptying occurs 
in ~30% and impaired gastric accommodation in up to 
40% of patients with functional dyspepsia134. Likewise, 
colonic transit is delayed in patients with IBS-C and 
accelerated in patients with IBS-D64. In patients cat-
egor ized as ‘severe IBS’, histo pathological alterations 
regarded as diagnostic for severe motility disorders100 
(such as inflammation and neuronal  degeneration in 
the myenteric plexus) have been observed135.
Consequently, there is a continuum ranging from 
mild disturbances that can be related to both functional 
disorders and pure motility disorders to severely dis-
turbed gastrointestinal motility, which is usually attrib-
uted to defined diseases such as gastro paresis, CIPO 
or slow-transit constipation. In most cases, differenti-
ation requires additional dimensions, including clinical 
Box 2 | Open research questions
• Studies comparing manometry and other clinical 
investigation of gastrointestinal motility and function 
with histological findings are required to better 
understand the pathophysiological basis of severe 
gastrointestinal dysfunction and the rationale for 
their treatment
• Clinical investigations that assess sensory function 
in patients with functional gastrointestinal disorders 
require validation
• The interactions of gastric and intestinal function and 
digestion are poorly defined in health and disease; tests 
that combine modalities could provide unique insight
• Outcome studies are required to assess indication for 
new interventions (for example, pyloric botulinum 
toxin injection, endoscopic pyloromyotomy and 
pyloroplasty) for less well-established dysfunctions 
(for example, pylorospasm).
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character istics, imaging and psychological traits, or the 
presence of underlying conditions and diseases that 
are associated with motility disturbances (for  example, 
 diabetes mellitus or Parkinson disease).
Conclusions
Disturbances of gastric and intestinal motor functions 
are frequent, and the rational use of gastrointestinal 
investigations is an important tool to establish the diag-
nosis and to guide treatment in such patients, but more 
work is needed (BOX 2). To gain clinically relevant and 
reliable information, adherence to standardized and ade-
quately validated study protocols is necessary. However, 
standardized study protocols validated in a large number 
of healthy individuals and patients are available for only 
some motility tests, and these include ROM and scinti-
graphic transit measurements. For several other tests, 
determination of a widely accepted standard is pending.
Complex, invasive investigations of gastrointestinal 
motility need to be limited to patients with severe disease 
and will remain available at specialized gastroentero-
logical centres only. By contrast, noninvasive tests such 
as 13C-GEBT and the WMC are increasingly available, 
such that knowledge of these tests and about gastro-
intestinal motility testing in general needs to be spread 
in the  medical community.
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